AVEO Pharmaceuticals — Investor Presentation (July 2021)
47 slides from AVEO Pharmaceuticals's investor presentation, Jul 16, 2021
Slide 1: FOTIVDA (tivozanib) in Renal Cell Carcinoma
FOTIVDA® (tivozanib) in Renal Cell Carcinoma July 16, 2021 Exhibit 99.1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained
Slide 3: Today's Speakers
Today’s Speakers Erick Lucera Chief Financial Officer Opening Remarks RCC Market and FOTIVDA Launch RCC Treatment Landscape TIVO-3 and FOTIVDA’s Role in the Treatment Landscape I-O Combo Landscape Thomas Hutson, D.O., Pharm.D. Baylor University Medical Center Brian Rini, M.D. Vanderbilt Ingram Cance
Slide 4: FOTIVDA (tivozanib) Now Approved
Full prescribing information available at www.FOTIVDA.com FOTIVDA® (tivozanib) NOW APPROVED FOTIVDA (tivozanib) is an oral, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory (R/R) advanced renal cel
Slide 5: A First Step Toward Sustainable Value Creation as an Integrated Commercial Company
A First Step Toward Potential Sustainable Value Creation as an Integrated Commercial Company ficlatuzumab ficlatuzumab Pipeline AV-380 AV-203 AV-353
Slide 6: RCC Treatment in Clinical Practice
RCC Treatment in Clinical Practice Thomas Hutson, D.O., Pharm.D.
Slide 7: Thomas Hutson: Conflict of Interest
Thomas Hutson, D.O., Pharm.D.: Conflict of Interest Research Support: AstraZeneca, AVEO, Bayer, BMS, Eisai, EMD Serono, Exelixis, Genentech, Gilead, Novartis Consulting: AstraZeneca, AVEO, Bayer, BMS, Eisai, EMD Serono, Exelixis, Genentech, Gilead, Novartis
Slide 8: Impact of immune checkpoint inhibitor therapy
Impact of immune checkpoint inhibitor therapy Use of immune checkpoint inhibitor (ICI) therapy first line has led to further improvement in overall survival compared with single-agent VEGF therapy1 However, data are lacking on how best to treat patients once they relapse following checkpoint inhibit
Slide 9: First-line ICI treatment options have expanded
First-line ICI treatment options have expanded
Slide 10: Use of ICIs first line has disrupted the treatment paradigm
Use of ICIs first line has disrupted the treatment paradigm Studies of TKIs as second-line therapy enrolled patients who had received single-agent TKIs first line1 However, the treatment paradigm has since evolved2,3 VEGFR inhibitor agents have clinical activity in mRCC that is refractory to ICI the
Slide 11: Post-2nd-line RCC therapy has proven benefits
Post−2nd-line RCC therapy has proven benefits 1. Wells JC, et al. Eur Urol. 2017;71(2):204-209. Post−second-line treatment can offer meaningful efficacy In retrospective analysis of treatment of 4824 International Metastatic Renal Cell Carcinoma Database Consortium patients with mRCC1: Patients who
Slide 12: Cumulative toxicity impacts treatment decisions post 2nd line
Cumulative toxicity impacts treatment decisions post 2nd line Adverse events may lead to dose reductions/interruptions, which may lead to underutilization or no treatment1-6 Tolerability issues may disrupt the treatment plan and its potential clinical benefits and may6-8: Negatively affect quality o
Slide 13: Common adverse events of regimens used in second- and third-line RCC
Common adverse events of regimens used in second- and third-line RCC Toxicity Cabozantinib Second and Third Line1 All (Grade 3/4) Axitinib Second Line2 All (Grade 3/4) Lenvatinib With Everolimus Second Line3 All (Grade 3/4) Sorafenib Second Line4 All (Grade 3/4) Hypertension 39% (16%) 40% (16%) 42%
Slide 14: Contemporary Trials in 3rd Line+ aRCC
Contemporary Trials in 3rd Line+ aRCC First Prospective Phase 3 data to help inform proper sequencing post-ICI therapy Drug Active Comparator Sample Size Primary Endpoint Results Regulatory Status Dovitinib Sorafenib N = 284 PFS mPFS 3.7 v 3.6 (not stat sig) Negative trial MK-6482 (Belzutifan) Evero
Slide 15: Need for effective and tolerable treatments in later-line RCC
There is a need for effective and tolerable treatments in later-line RCC Treatment decisions take into account safety, tolerability, comorbidities, and prior therapy,1 so the development of well-tolerated treatment options is essential Delaying symptoms is an essential goal: progressing symptomatic
Slide 16: TIVO-3 Data
TIVO-3 Data Brian Rini, M.D. VANDERBILT. School of Medicine
Slide 17: Brian Rini: Conflict of Interest
Brian Rini, M.D.: Conflict of Interest Research Support: Aravive, Arrowhead Pharmaceuticals, AstraZeneca, BMS, Dragonfly Therapeutics, Exelixis, Hoffman-LaRoche, Immunomedics, Incyte, Merck, Mirati Therapeutics, Pfizer, Seattle Genetics, Surface Oncology, Taris Consulting: 3DMedicines, Alkermes, Ara
Slide 18: FOTIVDA: A Differentiated VEGFR TKI
FOTIVDA: A Differentiated VEGFR 1, 2 and 3 TKI Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life designed to improve efficacy and tolerability Pawlowski N et al. AACR 2013. Poster 3971. Cabozantinib and lenvatinib are not shown because absolute oral bioavailabilities are not rep
Slide 19: TIVO-3: Pivotal Trial in RCC
TIVO-3: Pivotal Trial in RCC Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib to Sorafenib in Subjects With R/R Advanced RCC Results published in Lancet Oncology in December 2019 N = 350 Histologically / cytologically confirmed recurrent/metastatic RCC ECOG PS 0 o
Slide 20: TIVO-3 Demographics
TIVO-3 Demographics Characteristics sorry Median age, years 64 Male, % 73 IMDC Prognostic Risk, % Favorable 19 21 Intermediate 62 60 Poor 18 19 ECOG Performance Status, % (0/1) (49/50) (47/48) Region, % (NA/EU) (18/82) (15/85) Prior Lines of Therapy, % (2/3) (62/38) (59/41) Prior Treatment Regimen,
Slide 21: TIVO-3 Primary Endpoint: PFS of Tivozanib vs Sorafenib
: First Positive Phase 3 Dataset in Adult Patients Receiving Two or More Prior Systemic Therapies TIVO-3 Primary Endpoint: PFS of Tivozanib vs Sorafenib Survival Probability Treatment Group Source: PFS final analysis, Oct 4, 2018, U.S. FOTIVDA® Package Insert Tivozanib n=175 Sorafenib n=175 44% Impr
Slide 22: Tivozanib Median Duration of Response 2X Sorafenib
Tivozanib Median Duration of Response 2X Sorafenib Verzoni et al. ASCO 2021 Median DOR by investigator assessment Tivozanib20.3 months (95% CI, 9.8-29.9) Sorafenib 9.0 months (95% CI, 3.7-16.6)
Slide 23: Exploratory Analysis of Pre-Defined Subgroups
Exploratory Analysis of Pre-Defined Subgroups: Prior Checkpoint Inhibitor and TKI/TKI Porta et al. ASCO 2019 Other + VEGFR TKI: (N=100) HR=0.98; 95% CI 0.62; 1.56, ASCO GI 2019 Tivozanib Sorafenib Tivozanib Sorafenib Prior Checkpoint Inhibitor + VEGFR TKI Tivozanib (n = 47) Sorafenib (n = 44) Median
Slide 24: Safety & Tolerability
*Analysis as of Aug 15, 2019; ^Safety population **Includes fatigue and asthenia; † Includes hypertension, blood pressure increased, hypertensive crisis; § Includes diarrhea and frequent bowel movements.; # Includes dermatitis, dermatitis acneiform, dermatitis contact, drug eruption, eczema, eczema
Slide 25: Dose Modifications Due to TEAEs
Dose Modifications Due to TEAEs Pal et al ASCO 2021
Slide 26: TIVO-3: first positive Phase 3 dataset in two or more prior therapies
TIVO-3: first positive Phase 3 dataset in adult patients receiving two or more prior systemic therapies TIVO-3 is the first Phase 3 study in RCC that included a predefined population of patients who received prior immunotherapy Potential superior disease control (PFS, ORR & DoR) vs. sorafenib Most f
Slide 27: IO Combinations in RCC: TiNivo and TiNivo-2
IO Combinations in RCC: TiNivo and TiNivo-2 Laurence Albigès, M.D., Ph.D.
Slide 28: Laurence Albigès: Conflict of Interest
Laurence Albigès, M.D., Ph.D.: Conflict of Interest Research Support: BMS Consulting: Astellas, AstraZeneca, BMS, Corvus, EISAI, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer Guidelines panel: EUA RCC and ESMO RCC
Slide 29: Tivozanib Properties May Provide Unique Advantages in Combination with CPI
Nakamura K et al. Cancer Res 2006;66:9134–9142. Pawlowski N et al. AACR 2013. Poster 3971. Hammers, Emerging VEGF-I/O Combinations, ASCO 2017 Tivozanib Properties May Provide Unique Advantages in Combination with CPI Therapy Tolerability is Important in Combinations Tivozanib Significantly Reduces T
Slide 30: TiNivo: Phase 1/2 Data
Tivozanib (1.0 mg/day) QD/21 days + nivolumab 240 mg Q2 weeks N = 6 ECOG PS ≤ 1 and life expectancy ≥ 3 months Tivozanib (1.5 mg/day) QD/21 days + nivolumab 240 mg Q2 weeks Tivozanib (1.5 mg/day) QD/21 days + nivolumab 240mg Q2 weeks Phase 1 Phase 2 N = 22 ECOG PS ≤ 1 and life expectancy ≥ 3 months
Slide 31: TiNivo: Baseline Characteristics
TiNivo: Baseline Characteristics Albiges et al Annals of Oncology Nov 2020
Slide 32: TiNivo: Treatment Related Adverse Events
TiNivo: Treatment Related Adverse Events (>5% Any Grade) Albiges et al Annals of Oncology Nov 2020
Slide 33: Anti-tumor Activity Seen in Treatment Naive and Previously Treated Patients
Treatment Naïve (n=12) Pre-Treated (n=13) Includes 2 Prior CPI Pts Overall (n=25) CR 8% - 4% PR 42% 62% 52% ORR (CR+PR) 50% 62% 56% DCR (CR+PR+SD) 92% 100% 96% mPFS 18.9 mo (4.7, NR) NR* (11.0, NR) 18.9 mo (16.4, NR) Dose reductions 17% Nivolumab Mono2 Tivozanib Mono1 ORR 18% PFS 11.0 ORR 25% PFS 4.
Slide 34: Change in Tumor Size By Treatment Line
: Change in Tumor Size By Treatment Line
Slide 35: Opportunity To Establish New IO Sequencing Treatment Paradigm
Opportunity To Establish New IO Sequencing Treatment Paradigm IMDC PS Intermediate /Poor (~75%) Favorable (~25%) 1st Line 2nd Line IPI + Nivo - Checkmate-214 Avel + Axit vs Sunitinib - Javelin renal 101 Cabo + Nivo vs Sunitinib – Checkmate 9ER Pembro + Axit vs Sunitinib – Keynote 426 Pembro + Lenv v
Slide 36: Tivozanib+Nivolumab: Rationale for 2nd Line RCC Post IO
Tivozanib+Nivolumab: Rationale for 2nd Line RCC Post IO Tivozanib Properties Well suited for TKI+PD-1 Combination: Tivozanib is a well tolerated TKI as a single agent and in combination Tivozanib decreases T-Regs which may enhance PD-1 activity Changing Treatment Landscape in 1st line: Most patients
Slide 37: TiNivo-2: Pivotal Trial in RCC Following Prior Immunotherapy
TiNivo-2: Pivotal Trial in RCC Following Prior Immunotherapy Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare FOTIVDA® with OPDIVO® to FOTIVDA® Following Immunotherapy in RCC Patients Enrollment Expected to Start Mid-Year N = 326 Histologically / cytologically confirmed rec
Slide 38: RCC Market Opportunity
RCC Market Opportunity Mike Ferraresso
Slide 39: US RCC Market by Line of Therapy
US RCC Market by Line of Therapy1 1) Decision Resources Group projections 2022 Over 16,000 new first-line metastatic patients per year and growing, treatment advances in front line expected to increase size of R/R market 10,000 patients make it to 3rd and 4th line annually, nearly half of these late
Slide 40: RCC Treating Oncologist Survey: FOTIVDA Profile Attractive
RCC Treating Oncologist Survey: FOTIVDA Profile Attractive Source: AVEO Demand Study, September 2020 n=125, ZS 83% Of HCPs indicated they would be expected to prescribe FOTIVDA within 6 months of its availability to RCC patients 30% Of HCPs indicated they would be highly likely to increase their tre
Slide 41: Strategic Objectives for Launch
Strategic Objectives for Launch Educate and Raise Awareness “Data void” and tolerability challenges limit patient treatment rates in later line RCC Establish Tivozanib Differentiation Potent, selective, long half-life, down regulation of Tregs First positive Ph3 in adult patients with R/R advanced R
Slide 42: Commercial Launch Underway with Focused Oncology Team
Commercial Launch Underway: RCC Market Addressable with Focused Oncology Team Experienced oncology field force for effective market coverage (~65 FTEs) Commercially available to prescribe Team Deployment plan and Infrastructure designed for success through evolving COVID restrictions Oral oncology d
Slide 43: FOTIVDA Available Through a Limited Network of Specialty Pharmacies
FOTIVDA® (tivozanib) Is Available Through a Limited Network of Specialty Pharmacies and Distributors* Specialty Pharmacies (US) Biologics Onco360 Specialty Distributors (US) – Hospitals ASD Specialty Healthcare Cardinal Health Specialty Distribution McKesson Plasma & Biologics Specialty Distributors
Slide 44: The AVEO ACE Patient Support Program
Affordability Adherence Access START on Therapy STAY on Therapy QuickStart / Bridge Program Benefits Investigation Prior Authorization Support Denials / Appeals Support Copay Card Program Patient Assistance Program Alternative Funding Research Nurse Support Calls Patient / Caregiver Education Progra
Slide 45: Great Progress Despite COVID Access Challenges
Great Progress Despite COVID Access Challenges Key Launch Milestones FOTIVDA Commercially Available $1.1 Million Q1 Net Revenue Commercial Team Fully Deployed Encouraging uptake of FOTIVDA Patient Experience Samples Surpassed 300 TRxs A Leader in Share of Voice in R/R RCC MARCH 10TH MARCH 22ND END O
Slide 46: Q&A Session
Q&A Session Michael Bailey Chief Executive Officer Thomas Hutson, D.O., Pharm.D. Baylor University Medical Center Brian Rini, M.D. Vanderbilt Ingram Cancer Center Laurence Albigès, M.D., Ph.D. Gustave Roussy Institute Mike Ferraresso Chief Commercial Officer Michael Needle, M.D. Chief Medical Office
Slide 47: Thank You
Thank You M=O ONCOLOGY
AVEO Pharmaceuticals — Investor Presentation (July 2021) on 6ix